Abbonarsi

Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool - 19/06/20

Doi : 10.1016/j.ahj.2020.02.019 
Jafna L. Cox, MD a, b, c, , Ratika Parkash, MD a, Gary A. Foster, PhD d, e, Feng Xie, PhD f, g, James H. MacKillop, MD h, Antonio Ciaccia, MSc i, Shurjeel H. Choudhri, MD j, Laura M. Hamilton, MAHSR k, Joanna M. Nemis-White, BSc l, Lehana Thabane, PhD f, m, n, o, p

for the IMPACT-AF Investigators

a Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada 
b Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada 
c Heart and Stroke Foundation of Nova Scotia Endowed Chair in Cardiovascular Outcomes Research, Halifax, Nova Scotia, Canada 
d Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada 
e Biostatistics Unit, St Joseph's Healthcare, Hamilton, Ontario, Canada 
f Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada 
g Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada 
h Sydney Primary Care Medical Clinic, Sydney, Nova Scotia, Canada 
i Bayer Inc, Mississauga, Ontario, Canada 
j Bayer Inc, Mississauga, Ontario, Canada 
k QEII Health Sciences Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada 
l Strive Health Management Consulting Ltd, Halifax, Nova Scotia, Canada 
m Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada 
n Departments of Anesthesia/Pediatrics, McMaster University, Hamilton, Ontario, Canada 
o Biostatistics Unit, Centre for Evaluation of Medicine, McMaster University, Hamilton, Ontario, Canada 
p Population Health Research Institute (PHRI), Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada 

Reprint requests: Dr Jafna L. Cox, MD, Department of Medicine, Dalhousie University, QEII Health Sciences Ctr, Halifax Infirmary, 1796 Summer St, Room 2147, Halifax, Nova Scotia, Canada B3H 3A7.Department of MedicineDalhousie University, QEII Health Sciences CtrHalifax Infirmary, 1796 Summer St, Room 2147, HalifaxNova ScotiaCanadaB3H 3A7

Abstract

Background

Clinical decision support (CDS) tools designed to digest, filter, organize, and present health data are becoming essential in providing clinical and cost-effective care. Many are not rigorously evaluated for benefit before implementation. We assessed whether computerized CDS for primary care providers would improve atrial fibrillation (AF) management and outcomes as compared to usual care.

Methods

Overall, 203 primary care providers were recruited, randomized, and then cluster stratified by location (urban, rural) to usual care (n = 99) or CDS (n = 104). Providers recruited 1,145 adult patients with AF to participate. The intervention was access to an evidenced-based, point-of-care computerized CDS designed to support guideline-based AF management. The primary efficacy outcome was a composite of unplanned cardiovascular hospitalizations and AF-related emergency department visits; the primary safety outcome was major bleeding, both over 1 year. Patients were the units of intention-to-treat analysis.

Results

No significant effects on the primary efficacy (130 control, 118 CDS, hazard ratio: 0.98 [95% CI 0.71-1.37], P = .926) or safety (n = 7 usual care, n = 8 CDS, 1.3% total, P = .939) outcomes were observed at 12-months.

Conclusions

IMPACT-AF rigorously assessed a CDS tool in a highly representative sample of primary care providers and their patients; however, no impact on outcomes was observed. Considering the proliferating use of CDS applications, this study highlights the need for efficacy assessments prior to adoption and clinical implementation.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Unlabelled Image

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2020  The Author(s). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 224

P. 35-46 - Giugno 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality
  • Valeria Paradies, Huili Zheng, Mervyn H.H. Chan, Mark Yan Yee Chan, David C Foo, Chee W. Lee, Soo Tek Lim, Huay C. Tan, Jack Wei Chieh Tan, Khim L. Tong, Aaron S. Wong, Philip E. Wong, Khung Keong Yeo, Ling L. Foo, Terrance S. Chua, Tian H. Koh, Heerajnarain Bulluck, Derek J Hausenloy
| Articolo seguente Articolo seguente
  • Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
  • Yumin Gao, Eric Peterson, Neha Pagidipati

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.